TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Employees - 7, CEO - Mr. Thomas A. Fitzgerald M.B.A., Sector - Healthcare, Country - US, Market Cap - 9.81M

Altman ZScore(max is 10): -18.89, Piotroski Score(max is 10): 2, Working Capital: $4321502, Total Assets: $7294499, Retained Earnings: $-63201916, EBIT: -16728160, Total Liabilities: $9313233, Revenue: $0

- Current Price $0.42 - Analyst Target Price $10.00